Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GRFS
CUSIPN/A
Phone34-93-571-2200
Debt
Debt-to-Equity Ratio1.62%
Current Ratio3.01%
Quick Ratio1.35%
Price-To-Earnings
Trailing P/E Ratio18.78
Forward P/E Ratio15.42
P/E Growth1.31
Sales & Book Value
Annual Sales$4.88 billion
Price / Sales2.89
Cash Flow$1.4417 per share
Price / Cash14.33
Book Value$6.02 per share
Price / Book3.43
Profitability
EPS (Most Recent Fiscal Year)$1.10
Net Income$749.04 million
Net Margins15.46%
Return on Equity18.53%
Return on Assets6.07%
Miscellaneous
Employees14,877
Outstanding Shares682,820,000
